Recursion's CEO, Chris Gibson, stated that Lowe will primarily be used by the company's 500+ employees and is not planned to be offered as a product. However, the company may explore ways to give access to close partners and academic researchers in the future. The company is also looking at ways to enable the software to work on early-stage drug discovery with less human supervision.
Key takeaways:
- Utah-based company Recursion has developed a software platform called Lowe that uses a large-language learning model to serve as a natural language interface for complex drug discovery tasks.
- The platform allows scientists to ask questions of all the company’s models in tandem without having to code complex simulations on their own.
- The company plans to use Lowe primarily for its 500+ employees and does not plan to offer it as a product, but it may explore ways to give access to close partners and academic researchers in the future.
- Recursion is also looking for ways to enable its software to work on early stage drug discovery with less human supervision, potentially allowing the program to find and evaluate potential drugs and design experiments for human approval on its own.